Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
Annovis Bio is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to
be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of
the nerve cell, known as axonal transport. When this information flow is
impaired, the nerve cell gets sick and dies. The company expects its
treatment to improve memory loss and dementia associated with AD and
AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD
and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Neurocysticercosis the notorious vanishing ring enhancing lesion ijar feb 2015Sachin Adukia
This document summarizes a study of 25 patients presenting with ring enhancing lesions (RELs) on MRI brain scans. The study aimed to evaluate clinical features and diagnoses of RELs and treatment outcomes. Of the 25 patients, 8 (32%) were diagnosed with neurocysticercosis based on clinical features, investigations and MRI findings. All 8 neurocysticercosis patients presented with seizures and most with headache. Lesions were typically solitary and less than 10mm. Treatment with albendazole, anti-convulsants and steroids resulted in complete resolution in 6 patients (75%) and regression/calcification in the remaining 2, demonstrating neurocysticercosis has an excellent prognosis with appropriate treatment.
Neurological Pupil Index as an Indicator of Irreversible Cerebral Edema: A Ca...NeurOptics, Inc.
Assessing the pupillary light reflex (PLR) is acore component of neurological assessments. Changes in pupil size and reactivity can provide early recognition of neurological decline and facilitate lifesaving interventions.
This document discusses biomarkers for epileptogenesis and the challenges in developing clinically useful biomarkers to predict epilepsy risk, progression, and treatment response. It notes that while many potential biomarkers have been identified in preclinical studies, none have translated to clinical use. Some key challenges include the long timescales between injury and seizures, heterogeneity of epilepsy types and patients, and a focus on retrospective studies in refractory epilepsy patients rather than prospective validation. The document argues that combinatorial biomarkers analyzing multiple mechanisms may be more promising than single biomarkers, and that biomarkers should be validated as direct measures of patient outcomes rather than relying solely on seizure occurrence.
The document discusses home care for patients with neuromuscular diseases, specifically focusing on whether general practitioners or specialized teams are better suited to provide care. It notes the benefits of both approaches but emphasizes the importance of support networks and multidisciplinary teams to ensure accessible, high quality, and personalized care for patients.
Gavin Giovannoni - Brain health: why time matters in MSMS Trust
1) The document discusses the importance of early intervention in multiple sclerosis (MS) to maximize long-term brain health and prevent disability progression over time.
2) It promotes a strategy of treating MS patients aggressively early on to minimize clinical relapses, focal lesions detected by MRI, and underlying brain atrophy.
3) The goal is to create an initiative called MS Brain Health that encourages adopting a therapeutic approach aiming to optimize brain health for all people living with MS through their lifetime.
Isolated central nervous system tuberculosis is uncommon in immunocompetent patients. It resembles a pyogenic brain abscess
clinically and radiologically and poses a problem in diagnosis and treatment. Here we described a case of recurrent frontal lobe
abscess, which was diagnosed as a tubercular abscess. There was no clinical or radiological evidence of active tuberculosis
elsewhere in the body. The diagnosis of tubercular abscess was confirmed by Mycobacterium tuberculosis by Polymerase Chain
Reaction (TB-PCR) in the abscess material aspirated via a burr hole.
This study evaluated the effects of citicoline treatment on outcomes for 173 acute ischemic stroke patients treated at three Mexican hospitals. 86 patients received citicoline within 48 hours of stroke onset, while 87 untreated patients served as controls matched for age, gender and severity. Compared to controls, citicoline exposure was associated with lower functional impairment as measured by mRS at 30 days. Multivariate analysis found citicoline independently associated with lower 90-day mortality and fewer in-hospital complications like infections. The study suggests citicoline may provide benefits, but as an observational study rather than randomized trial, the results only show clinical associations.
Long-term cognitive impairment after critical illness (CIACI) is frequently reported in up to 66% of patients three months after intensive care hospitalization. The condition has overlapping neurological changes with stroke, traumatic brain injury, and neurodegenerative disorders. Risk factors for CIACI include depression, biomarkers for Alzheimer's disease, delirium duration during hospitalization, and exposure to certain drugs. Current strategies to prevent or treat CIACI focus on reducing delirium and agitation, as well as physical and cognitive rehabilitation. Neurotrophic factors may play a role in neurogenesis, blood-brain barrier integrity, and neuronal repair, suggesting they could be a potential target for novel CIACI treatments.
This document discusses what brain health is in the context of multiple sclerosis (MS). It provides an overview of factors related to brain health for people with MS, including risks, symptoms, diagnostic criteria, treatments, management strategies, and lifestyle factors. The document emphasizes that early intervention and treatment is important for brain health in MS, as time matters, and delayed treatment can lead to worse long-term outcomes and prognosis. It presents evidence that earlier treatment may provide benefits in reducing relapses and disability progression.
Hypothermia for Neonatal Hypoxic Ischemic EncephalopathyMaged Zakaria
This review article summarizes the current evidence on therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy (HIE) from randomized controlled trials. The review identified 7 trials including 1214 newborns that compared therapeutic hypothermia to normothermia. The results showed that therapeutic hypothermia reduced the risk of death or major neurodevelopmental disability at 18 months and increased the rate of survival with normal neurological function. Both total body cooling and selective head cooling were effective in reducing these risks. The review concludes that hypothermia improves outcomes for newborns with moderate to severe HIE and should be considered as part of routine clinical care for these newborns.
This study compared intravenous levetiracetam (LEV) to intravenous phenytoin (PHT) for seizure prophylaxis in patients with severe traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH) admitted to the neuroscience intensive care unit (NSICU). Fifty-two patients were randomized to receive either LEV (n=34) or PHT (n=18). Continuous EEG monitoring was performed for 72 hours. Long-term outcomes including Disability Rating Scale scores and Glasgow Outcome Scale scores were better in the LEV group compared to the PHT group at 3 and 6 months, respectively, after controlling for baseline severity. There were no significant differences in seizure rates
This randomized controlled trial evaluated whether pre-hospital administration of hypertonic saline or hypertonic saline plus dextran improved 6-month neurological outcomes in patients with severe traumatic brain injury without hypovolaemic shock compared to normal saline. Over 1300 patients were randomized to receive one of the three study fluids. The primary outcome of an extended Glasgow Outcome Scale score of ≤4 at 6 months was not significantly different between groups. Secondary outcomes including 28-day survival were also not significantly different between groups. The study was terminated early due to futility in showing benefit of the hypertonic fluids over normal saline.
This document lists publications by Kari J. Reinikainen including original papers, reviews, and pharmaceutical experience. It provides a list of 48 publications from 1978-1991 related to neurology, neurotransmitters, Alzheimer's disease, and other topics. Reinikainen's publications examined changes in neurotransmitters and receptors in Alzheimer's disease and other conditions. Many publications involved analysis of cerebrospinal fluid markers and post-mortem brain tissue. Reinikainen's work contributed to understanding of neurochemical changes in neurological and psychiatric conditions.
Neurosarcoidosis is a rare condition where sarcoidosis affects the nervous system. It can be difficult to diagnose as it often presents with non-specific neurological symptoms. Diagnosis requires a combination of CSF analysis, MRI imaging showing characteristic abnormalities, and biopsy evidence of granulomas. A multidisciplinary team approach is needed to manage this complex condition.
This document discusses progressive multiple sclerosis (MS) and whether it is possible to prevent or slow its progression. It begins by acknowledging potential conflicts of interest from clinical trials and industry relationships. It then explains that relapsing and progressive MS are part of a continuum, with continuous tissue loss driving progression even during relapsing stages. While symptoms and deficits differ depending on tissue loss and brain reserve, MS remains a single disease. Later stages are determined more by neuroanatomy and length of affected nerve fibers. The document advocates considering progressive MS patients' expectations realistically and evaluating therapies based on proven efficacy in both relapsing and progressive MS as well as safety and convenience factors.
Si nous portions un nouveau regard sur le syndrome d'encéphalite aiguë chez le sujet jeune ? Il faut penser aujourd'hui à évoquer l'Encéphalite Auto-Immune à Anticorps Anti-Récepteurs NMDA ! Vous sauverez des vies à l'évoquer devant toute épilepsie atypique et/ou psychose inaugurale associée à un signe discordant.
Spinal Cord Stimulation Dr Andrew Crockettepicyclops
1. The document discusses spinal cord stimulation service, including its history, components, mechanisms of action, indications, procedures, evidence from studies, outcomes, complications, and guidelines.
2. It provides details on the multidisciplinary team approach used, case studies, audits of outcomes that found over 50% pain relief in many patients, and complications rates of around 30-40%.
3. The document reflects on the author's experience with the multidisciplinary team approach and how working with complex patients has been an enjoyable learning experience.
Is It Important to Determine Who Will Develop Alzheimer’s?Ross Finesmith
This document discusses whether it is important to determine who will develop Alzheimer's disease. While past studies tried to predict who would develop Alzheimer's, the information had little clinical benefit when there were no effective treatments. New research using blood biomarkers has shown promise in identifying over 90% of cognitively normal individuals who will develop mild cognitive impairment or Alzheimer's within a few years. If pre-clinical individuals can be identified, disease-modifying treatments targeted to prevent irreversible pathological changes may prove useful by preventing manifestation of the disease.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing
Phase 2a study in AD patients and a second Phase 2a study in early PD and early AD patients.
Neurocysticercosis the notorious vanishing ring enhancing lesion ijar feb 2015Sachin Adukia
This document summarizes a study of 25 patients presenting with ring enhancing lesions (RELs) on MRI brain scans. The study aimed to evaluate clinical features and diagnoses of RELs and treatment outcomes. Of the 25 patients, 8 (32%) were diagnosed with neurocysticercosis based on clinical features, investigations and MRI findings. All 8 neurocysticercosis patients presented with seizures and most with headache. Lesions were typically solitary and less than 10mm. Treatment with albendazole, anti-convulsants and steroids resulted in complete resolution in 6 patients (75%) and regression/calcification in the remaining 2, demonstrating neurocysticercosis has an excellent prognosis with appropriate treatment.
Neurological Pupil Index as an Indicator of Irreversible Cerebral Edema: A Ca...NeurOptics, Inc.
Assessing the pupillary light reflex (PLR) is acore component of neurological assessments. Changes in pupil size and reactivity can provide early recognition of neurological decline and facilitate lifesaving interventions.
This document discusses biomarkers for epileptogenesis and the challenges in developing clinically useful biomarkers to predict epilepsy risk, progression, and treatment response. It notes that while many potential biomarkers have been identified in preclinical studies, none have translated to clinical use. Some key challenges include the long timescales between injury and seizures, heterogeneity of epilepsy types and patients, and a focus on retrospective studies in refractory epilepsy patients rather than prospective validation. The document argues that combinatorial biomarkers analyzing multiple mechanisms may be more promising than single biomarkers, and that biomarkers should be validated as direct measures of patient outcomes rather than relying solely on seizure occurrence.
The document discusses home care for patients with neuromuscular diseases, specifically focusing on whether general practitioners or specialized teams are better suited to provide care. It notes the benefits of both approaches but emphasizes the importance of support networks and multidisciplinary teams to ensure accessible, high quality, and personalized care for patients.
Gavin Giovannoni - Brain health: why time matters in MSMS Trust
1) The document discusses the importance of early intervention in multiple sclerosis (MS) to maximize long-term brain health and prevent disability progression over time.
2) It promotes a strategy of treating MS patients aggressively early on to minimize clinical relapses, focal lesions detected by MRI, and underlying brain atrophy.
3) The goal is to create an initiative called MS Brain Health that encourages adopting a therapeutic approach aiming to optimize brain health for all people living with MS through their lifetime.
Isolated central nervous system tuberculosis is uncommon in immunocompetent patients. It resembles a pyogenic brain abscess
clinically and radiologically and poses a problem in diagnosis and treatment. Here we described a case of recurrent frontal lobe
abscess, which was diagnosed as a tubercular abscess. There was no clinical or radiological evidence of active tuberculosis
elsewhere in the body. The diagnosis of tubercular abscess was confirmed by Mycobacterium tuberculosis by Polymerase Chain
Reaction (TB-PCR) in the abscess material aspirated via a burr hole.
This study evaluated the effects of citicoline treatment on outcomes for 173 acute ischemic stroke patients treated at three Mexican hospitals. 86 patients received citicoline within 48 hours of stroke onset, while 87 untreated patients served as controls matched for age, gender and severity. Compared to controls, citicoline exposure was associated with lower functional impairment as measured by mRS at 30 days. Multivariate analysis found citicoline independently associated with lower 90-day mortality and fewer in-hospital complications like infections. The study suggests citicoline may provide benefits, but as an observational study rather than randomized trial, the results only show clinical associations.
Long-term cognitive impairment after critical illness (CIACI) is frequently reported in up to 66% of patients three months after intensive care hospitalization. The condition has overlapping neurological changes with stroke, traumatic brain injury, and neurodegenerative disorders. Risk factors for CIACI include depression, biomarkers for Alzheimer's disease, delirium duration during hospitalization, and exposure to certain drugs. Current strategies to prevent or treat CIACI focus on reducing delirium and agitation, as well as physical and cognitive rehabilitation. Neurotrophic factors may play a role in neurogenesis, blood-brain barrier integrity, and neuronal repair, suggesting they could be a potential target for novel CIACI treatments.
This document discusses what brain health is in the context of multiple sclerosis (MS). It provides an overview of factors related to brain health for people with MS, including risks, symptoms, diagnostic criteria, treatments, management strategies, and lifestyle factors. The document emphasizes that early intervention and treatment is important for brain health in MS, as time matters, and delayed treatment can lead to worse long-term outcomes and prognosis. It presents evidence that earlier treatment may provide benefits in reducing relapses and disability progression.
Hypothermia for Neonatal Hypoxic Ischemic EncephalopathyMaged Zakaria
This review article summarizes the current evidence on therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy (HIE) from randomized controlled trials. The review identified 7 trials including 1214 newborns that compared therapeutic hypothermia to normothermia. The results showed that therapeutic hypothermia reduced the risk of death or major neurodevelopmental disability at 18 months and increased the rate of survival with normal neurological function. Both total body cooling and selective head cooling were effective in reducing these risks. The review concludes that hypothermia improves outcomes for newborns with moderate to severe HIE and should be considered as part of routine clinical care for these newborns.
This study compared intravenous levetiracetam (LEV) to intravenous phenytoin (PHT) for seizure prophylaxis in patients with severe traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH) admitted to the neuroscience intensive care unit (NSICU). Fifty-two patients were randomized to receive either LEV (n=34) or PHT (n=18). Continuous EEG monitoring was performed for 72 hours. Long-term outcomes including Disability Rating Scale scores and Glasgow Outcome Scale scores were better in the LEV group compared to the PHT group at 3 and 6 months, respectively, after controlling for baseline severity. There were no significant differences in seizure rates
This randomized controlled trial evaluated whether pre-hospital administration of hypertonic saline or hypertonic saline plus dextran improved 6-month neurological outcomes in patients with severe traumatic brain injury without hypovolaemic shock compared to normal saline. Over 1300 patients were randomized to receive one of the three study fluids. The primary outcome of an extended Glasgow Outcome Scale score of ≤4 at 6 months was not significantly different between groups. Secondary outcomes including 28-day survival were also not significantly different between groups. The study was terminated early due to futility in showing benefit of the hypertonic fluids over normal saline.
This document lists publications by Kari J. Reinikainen including original papers, reviews, and pharmaceutical experience. It provides a list of 48 publications from 1978-1991 related to neurology, neurotransmitters, Alzheimer's disease, and other topics. Reinikainen's publications examined changes in neurotransmitters and receptors in Alzheimer's disease and other conditions. Many publications involved analysis of cerebrospinal fluid markers and post-mortem brain tissue. Reinikainen's work contributed to understanding of neurochemical changes in neurological and psychiatric conditions.
Neurosarcoidosis is a rare condition where sarcoidosis affects the nervous system. It can be difficult to diagnose as it often presents with non-specific neurological symptoms. Diagnosis requires a combination of CSF analysis, MRI imaging showing characteristic abnormalities, and biopsy evidence of granulomas. A multidisciplinary team approach is needed to manage this complex condition.
This document discusses progressive multiple sclerosis (MS) and whether it is possible to prevent or slow its progression. It begins by acknowledging potential conflicts of interest from clinical trials and industry relationships. It then explains that relapsing and progressive MS are part of a continuum, with continuous tissue loss driving progression even during relapsing stages. While symptoms and deficits differ depending on tissue loss and brain reserve, MS remains a single disease. Later stages are determined more by neuroanatomy and length of affected nerve fibers. The document advocates considering progressive MS patients' expectations realistically and evaluating therapies based on proven efficacy in both relapsing and progressive MS as well as safety and convenience factors.
Si nous portions un nouveau regard sur le syndrome d'encéphalite aiguë chez le sujet jeune ? Il faut penser aujourd'hui à évoquer l'Encéphalite Auto-Immune à Anticorps Anti-Récepteurs NMDA ! Vous sauverez des vies à l'évoquer devant toute épilepsie atypique et/ou psychose inaugurale associée à un signe discordant.
Spinal Cord Stimulation Dr Andrew Crockettepicyclops
1. The document discusses spinal cord stimulation service, including its history, components, mechanisms of action, indications, procedures, evidence from studies, outcomes, complications, and guidelines.
2. It provides details on the multidisciplinary team approach used, case studies, audits of outcomes that found over 50% pain relief in many patients, and complications rates of around 30-40%.
3. The document reflects on the author's experience with the multidisciplinary team approach and how working with complex patients has been an enjoyable learning experience.
Is It Important to Determine Who Will Develop Alzheimer’s?Ross Finesmith
This document discusses whether it is important to determine who will develop Alzheimer's disease. While past studies tried to predict who would develop Alzheimer's, the information had little clinical benefit when there were no effective treatments. New research using blood biomarkers has shown promise in identifying over 90% of cognitively normal individuals who will develop mild cognitive impairment or Alzheimer's within a few years. If pre-clinical individuals can be identified, disease-modifying treatments targeted to prevent irreversible pathological changes may prove useful by preventing manifestation of the disease.
The document summarizes 10 healthcare innovation projects presented at the DayOne Conference. The projects cover a range of areas including biomarkers and disease monitoring, digital health platforms to improve communication between patients and doctors, technologies for more precise diagnosis and treatment, and systems to empower patients and improve healthcare delivery. Many of the projects utilize new technologies like artificial intelligence, mobile apps, and sensors to work towards more preventative, personalized, and cost-effective healthcare.
Medicines For Respiratory Diseases
Apneas: Types, Their Measurement, Epidemiology, and Economics
Dronabinol: Breakthrough Treatment for Obstructive Sleep
Apnea
"Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit, the same word means both breath and life."
Abbot George Burke
Brief Report: OSA Evaluations for the Anaesthesiologist, Surgeon, Surgery Centresemualkaira
This short report presents a scope of the medical condition of Obstructive Sleep Apnea (OSA). Current methods for assessment and
diagnosis of OSA are presented. Complications and potential death
from untreated OSA places the anesthesiologist, surgeon and surgical center in a risk situation. Factors related to the risk factors
and points toward resolution are presented.
Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear...Andrew Stephens
Piramal Imaging will present new research on positron emission tomography (PET) imaging tracers at the Society of Nuclear Medicine and Molecular Imaging annual meeting, including data on the approved amyloid imaging agent florbetaben F18 and several investigational agents. Five abstracts provide new analyses on the clinical applications and impact of florbetaben amyloid-PET imaging. Additional abstracts present promising clinical trial data on the investigational tau tracer PI-2620 and agents for thrombus imaging (F-GP1) and cancer imaging (F-FSPG and Ga-RM2). Piramal Imaging aims to advance molecular imaging through developing novel PET tracers.
Day one conference projects with journey mapsDayOne
DayOne Conference 2019 projects and journey maps. 30 ventures presented their solutions and together with conference participants built a journey map of their future.
Alzheimer's Disease and Other Dementias by ARLYN M. VALENCIA , M.D.. Neurolog...Arlyn Valencia, M.D.
This document discusses Alzheimer's disease and other dementias. It defines Alzheimer's disease as a neurodegenerative disease caused by amyloid plaques and tau tangles in the brain. It differentiates Alzheimer's from other dementias such as frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, and normal pressure hydrocephalus. The document discusses risk factors, symptoms, diagnostic tools, treatments, and future targets for therapies for Alzheimer's and other dementias.
UCSF08 - EPGP_Pharmacogenomics_Award_2008_SubmissionMichael Williams
The document describes a pharmacogenomics research informatics project at the University of California, San Francisco called the Epilepsy Phenome Genome Project (EPGP). The EPGP received $15 million to study the genetic factors underlying common forms of epilepsy. It involves collecting detailed phenotypic data on epilepsy patients and controls to identify genetic contributions to epilepsy, brain development anomalies, and responses to antiepileptic drug (AED) treatments. The project developed a web-based tool to efficiently capture pharmacogenomics data across 15 EPGP clinical sites. This tool collects detailed AED drug histories and will provide an immense source of new knowledge to better understand genetic influences on drug resistance and potentially enable personalized epilepsy treatment.
ACT is conducting three clinical trials for dry age-related macular degeneration (AMD) and Stargardt's disease (SMD) using retinal pigment epithelium (RPE) cells derived from human embryonic stem cells. The trials have shown no adverse events and persistence of the transplanted cells, with functional vision improvements in most patients. ACT has additional clinical programs planned or underway for myopic macular degeneration and has a pipeline of other ophthalmology and regenerative medicine programs. It has strong intellectual property around RPE cell production and therapy. Upcoming milestones include further patient follow-up data and the potential start of Phase II trials. ACT is led by an experienced management team and board of directors.
The document discusses several developments for treating inherited neuropathies:
1) The first gene therapy clinical trial to treat an inherited neuropathy, Giant Axonal Neuropathy, is approved. It will deliver a healthy copy of the GAN gene to spinal cord nerves using an AAV9 viral vector.
2) The Hereditary Neuropathy Foundation is creating a directory of expert healthcare providers for Charcot-Marie-Tooth and providing them resources to improve diagnosis and care.
3) An advisory board meeting was held to discuss the Foundation's research funding to date and future goals, including several projects aimed at developing treatments for CMT and related diseases.
Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?Aranca
Could a vaccine for Alzheimer's be a reality any sooner? Find more on Alzheimer Therapy Market Challenges from Aranca's Technology Intelligence & IP Research Experts.
The document provides an introduction to the Buck Institute's Alzheimer's/Mild Cognitive Impairment Program. It summarizes that the program aims to develop novel therapeutic candidates for Alzheimer's disease by identifying compounds that interact with the amyloid precursor protein (APP) or other members of the underlying biological network. Three classes of drug candidates are being researched: 1) the endogenous protein netrin-1, 2) several small molecule compounds identified in screens, including a lead candidate called F03, and 3) analogs of F03 and other hits with improved properties. The Buck Institute is pursuing clinical development of F03 and seeking partners to collaborate on additional candidate drugs.
Background on the 30 projects pitching at the DayOne Conference on 9th September 2019. At the conference the projects will be assisted by mentors and conference participants to create a journey map to help them on their path to healthcare innovation.
This document discusses strategies for brain relaxation in neurocritical patients. It begins by defining brain relaxation as a balanced relationship between brain volume and cranial capacity after craniectomy. It then covers physiological bases, diagnosis and classification. Risk factors for inadequate brain relaxation are discussed from two studies, including tumor size and location. Interventions to achieve brain relaxation are also summarized, including pharmacological options like mannitol, hypertonic saline and steroids as well as non-pharmacological techniques like patient positioning, ventilation strategies and CSF drainage. Overall, the document provides an overview of concepts and current approaches for brain relaxation in neurosurgical patients.
PRA Insights Report: Alzheimer's Disease ResearchEmma Whieldon
(1) The document summarizes the results of a survey conducted at the 2017 Alzheimer's Association International Conference to gather insights on Alzheimer's disease research. (2) Over half of respondents believed the foremost challenge in neuroscience drug development is target identification. (3) The amyloid hypothesis was seen as the most promising research area, though tau protein and inflammation were also viewed as important. (4) Pre-screening subjects in the community was believed to have the biggest positive impact on recruiting prodromal Alzheimer's patients.
POWERPOINT PRESENTATION ON PATHOPHYSIOLOGY OF ALZHEIM.docxstilliegeorgiana
POWERPOINT PRESENTATION ON:
PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE
TANIA GONZALEZ DIAZ
WALDEN UNIVERSITY
NURS:6501C
AUGUST 03,2019
*
Alzheimer’s disease
Alzheimer disease (AD) is: Chronic neurodegenerative disorder
The leading cause of dementia
According to Etindele Sosso, Nakamura & Nakamura (2017), as of 2015, 29.8 million people had AD.
Most prevalent among people whose ages are 65 years and above.
Alzheimer disease (AD) is a chronic neurodegenerative disorder that normally starts and gradually progresses with the brain cells dying off. Leading to memory loss. The leading cause of dementia which affects an individual cognitive, social and behavioral skills that destroy the capability of a person to function properly.According to Etindele Sosso, Nakamura & Nakamura (2017), as of 2015, there were 29.8 million people globally who had AD. It mostly starts in people whose ages are over 65 years.
*
Pathophysiology of Alzheimer’s Disease Exact cause is unknown. Early onset of Familial Alzheimer’s Disease is associated with 3 genes found in chromosome 21, namely; Abnormal amyloid precursor protein 14 [APP14] Abnormal presenilin 1 [PSEN1] andAbnormalpresenilin 2 [PSEN2])Late onset of AD is related to changes in apolipoprotein E gene-allele4(APOE4) gene found in chromosome 19. Source: (Huether, McCance, Brashers & Rote, 2016)
The exact cause of AD is still unknown till date. Early onset of Familial Alzheimer’s Disease is associated with 3 genes found in chromosome 21, namely; Abnormal amyloid precursor protein 14 [APP14] Abnormal presenilin 1 [PSEN1] andAbnormalpresenilin 2 [PSEN2])Late onset of AD is related to changes in apolipoprotein E gene-allele 4 (APOE4) gene found in chromosome 19.
*
Pathophysiology of Alzheimer’s Disease …contdDNA methylation is one epigenetic markers for AD.Pathological alterations in the brain causes the loss of memory.These pathological alterations include; Accumulation of extracellular neuritic plaques with core of amyloid Degeneration of basal forebrain ß-protein Intraneuronal neurofibrillary tanglescholinergic neurons with loss of acetylcholineSource: (Huether, McCance, Brashers & Rote, 2016)
DNA methylation is one epigenetic markers for AD.Pathological alterations in the brain causes the loss of memory.These pathological alterations include; Accumulation of extracellular neuritic plaques with core of amyloid ß-protein Intraneuronal neurofibrillary tanglesDegeneration of basal forebrain cholinergic neurons If the brain is unable to get rid of amyloid the precursor protein, toxic fragments of amyloid ß-protein accumulates and which trigger neuritic plaques to diffuse, the transmission of impulses by nerve cells to be disrupted and the nerve cells to die. The tau protein in neiurons detaches forming an insoluble neurofibrillary tangles, which causes the neurons to die. Neurofibrilary tangles and neuritic plaques which are more concentrated in the cerebral cortex are the one that contribute t ...
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Docola has developed a healthcare communication platform that utilizes asynchronous telehealth to deliver patient education and support. Their proprietary platform currently has over 55,000 patient users and over 1,100 clinician users. Docola seeks to raise up to $500,000 through a convertible note to fund working capital, research and development, and costs associated with an upcoming IPO.
- INNO Holdings is presenting an IPO investor presentation for an initial public offering on the NASDAQ Capital Market.
- The company manufactures prefabricated steel building components and systems using proprietary technology to reduce construction costs and environmental impact.
- INNO Holdings has four initial product lines - metal studs, prefabricated housing units, modular apartment buildings, and a mobile factory system. It aims to disrupt the construction industry through standardized, sustainable construction methods.
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a biotech company developing immune monitoring and immune modulation platforms. Its AditxtScore platform can provide comprehensive immune profiles to monitor responses to pathogens, vaccines, drugs and transplants. Its Adimune platform aims to modulate the immune system to treat conditions like psoriasis, type 1 diabetes, and increase skin allograft survival. The company is working to develop, operate and commercialize these platforms. It currently generates revenue from immune monitoring tests and expects revenue from licensing deals for immune modulation programs as they advance in clinical trials towards commercialization.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
KEY Points of Leicester travel clinic In London doc.docxNX Healthcare
In order to protect visitors' safety and wellbeing, Travel Clinic Leicester offers a wide range of travel-related health treatments, including individualized counseling and vaccines. Our team of medical experts specializes in getting people ready for international travel, with a particular emphasis on vaccines and health consultations to prevent travel-related illnesses. We provide a range of travel-related services, such as health concerns unique to a trip, prevention of malaria, and travel-related medical supplies. Our clinic is dedicated to providing top-notch care, keeping abreast of the most recent recommendations for vaccinations and travel health precautions. The goal of Travel Clinic Leicester is to keep you safe and well-rested no matter what kind of travel you choose—business, pleasure, or adventure.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...nirahealhty
The South Beach Coffee Java Diet is a variation of the popular South Beach Diet, which was developed by cardiologist Dr. Arthur Agatston. The original South Beach Diet focuses on consuming lean proteins, healthy fats, and low-glycemic index carbohydrates. The South Beach Coffee Java Diet adds the element of coffee, specifically caffeine, to enhance weight loss and improve energy levels.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
PET CT beginners Guide covers some of the underrepresented topics in PET CT
Annovis Bio (ANVS) Presentation - May 7, 2020
1. Attacks Alzheimer’s Disease and
Neurodegeneration by Improving the
Information Highway of the Nerve Cell
Axonal Transport
M a y 2 0 2 0
Symbol: ANVS (NYSE American)
2. FORWARD-LOOKING STATEMENTS
Statements in this presentation contain “forward-looking statements” that are subject to
substantial risks and uncertainties. Forward-looking statements contained in this presentation
may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,”
“may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and
include, without limitation, statements regarding Annovis Bio, Inc.’s expectations regarding
the trading of its shares on the NYSE American market. Forward-looking statements are
based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to be accurate. These
and other risks and uncertainties are described more fully in the section titled “Risk Factors”
in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the
Securities and Exchange Commission. Forward-looking statements contained in this
presentation are made as of this date, and Annovis Bio, Inc. undertakes no duty to update
such information except as required under applicable law.
2
3. 3
Annovis is developing drugs for Alzheimer's (AD) and Parkinson's disease (PD),
including the orphan indication Alzheimer's in Down Syndrome (AD-DS)
Three patented families of compounds
Lead compound, ANVS401, is the only drug to improve axonal transport, the
information highway of the nerve cell, by attacking multiple neurotoxic proteins
Two phase 2a studies
AD trial already underway
PD trial to be initiated
Successful completion of the two phase 2a will allow start of two phase 3 studies
AD-DS
PD
Highly experienced and respected management team, great board and world
renowned scientific advisory board
HIGHLIGHTS
A novel approach to treat neurodegeneration is desperately needed
4. THE STATE OF ALZHEIMER’S DISEASE
Alzheimer's is the most common cause of dementia, a
general term for memory loss and other cognitive
abilities serious enough to interfere with daily life.
Alzheimer's disease accounts for 60 to 80 percent of
dementia cases.
1 in 6 females and 1 in 11 males have the chance to
develop Alzheimer's during the remainder of their lives
at age 65.
From 1998 to 2018 there have been over 500 failed
attempts at developing Alzheimer's drugs.
The sector needs to rethink dementia, develop new
approaches and create new drugs.
4
5. ALZHEIMER’S DRUG TRIAL FAILURES
Have researchers been on the wrong track with amyloid?
5
The idea that sticky brain plaques cause Alzheimer’s disease began as an
interesting hypothesis and eventually became drug industry dogma. Now, after a
string of clinical trial failures, that hypothesis looks less credible than ever. But
how did nearly two decades of failure not convince the brightest minds in pharma
that it was time to move on?
Damian Garde & Alex Hogan
After amyloid failures, it’s
time to take a new tack
for treating Alzheimer’s
Raymond J. Tesi STAT News April 30, 2019
Aducanumab's failure puts
pressure on field to look
beyond amyloid
Ned PagliaruloMarch 22, 2019
Amyloid Plaque and Aβ is NOT The Only Answer
6. Chronic and acute brain insults lead to high levels of neurotoxic proteins,
to inflammation and neurodegeneration
Attacking one neurotoxic protein results in minimal effect
ANVS401 is the only drug to attack multiple neurotoxic proteins simultaneously
Amyloid β
AD / PD- Aβ Targeting Compounds
ANNOVIS’ DRUG TREATS AD AND PD
Tau
Tauopathies - AD - Tau Targeting Compounds
aSynuclein
PD / AD - aSYN Targeting Compounds
6
ACTIVATED MICROGLIA = High Inflammation
7. DISEASE
NEUROTOXIC PROTEIN
TARGET PRE-CLINICAL IND PHASE 1 PHASE 2
AD
AD-DS
PD
TBI
Advanced
AD
APP, tau, aSYN
APP, tau, aSYN
aSYN, APP, tau
tau, APP, aSYN
BChEl
PIPELINE
Oral drug for chronic
indications
injectabledrug for acute
traumatic events
oral drug for advancedAD
and dementia
7
8. 8
CORPORATE PATENT ESTATE
Patent/Application Subject Matter Status US Expiry US
PCT
ANVS401 and 405 - Method of use of MOA
for prevention and treatment of diseases
Pending 2038
PCT ANVS405 - Acute brain and nerve injuries Pending 2036
PCT
ANVS401 - pK/pD, low doses, formulations
Neurodegenerative Diseases
US 10,383,851
Issued August 2019
2031
In-licensed
patents
Composition of matter, manufacturing,
method for treating AD and DS
Granted 2022-25
Composition
of Matter and
Method of Use
Process for
Production
Methods of Use:
pK/pD, Dose,
Formulations
Method of Use:
Acute Brain
and Nerve
Injuries
Method of Use:
Prevention
and Treatment
Multi-layer strategy
9. NEUROTRANSITTERS
THAT TRAVEL ACCROSS
THE AXON
Adrenaline
Noradrenaline
Dopamine
HOW NERVE CELLS WORK
In healthy nerve cells little packages containing neurotransmitters or nerve growth factors
travel unimpaired from the cell body through the axon to the synapse.
SOMA &
CELL BODY
DENDRITES
Serotonin
Gaba
Acetylcholine
Glutamine
Endorphins
SYNAPSE
9
Neurotoxic proteins limit the flow and speed at which
neurotransmitters travel along the axon resulting
in compromised nerve function
T H E I N F O R M A T I O N H I G H W A Y
10. NEUROTOXIC PROTEINS IMPAIR AXONAL
TRANSPORT AND CAUSE A TOXIC CASCADE
ANVS401 IMPROVES AXONAL TRANSPORT
AND IMPEDES THE TOXIC CASCADE
IMPAIRED AXONAL TRANSPORT
SLOWER SYNAPTIC TRANSMISSION
INFLAMMATION
DEATH OF NERVE CELLS
LOSS OF COGNITIVE AND
MOTOR FUNCTION
IMPROVED AXONAL TRANSPORT
INCREASED SYNAPTIC TRANSMISSION
NO INFLAMMATION
HEALTHY NERVE CELLS
IMPROVED COGNITIVE AND
MOTOR FUNCTION
HIGH LEVELS OF NEUROTOXIC
PROTEINS
ANVS401 LOWERS LEVELS OF
NEUROTOXIC PROTEINS
11. NEURODEGENERATION IS AN AXONAL TRANSPORT
DISEASE
Axonal transport is responsible for: Normal Transport
The Normal Flow and Speed of vesicles carrying BDNF across the axon.
Neurotransmitters GABA
(anxiety), ACh (cognition),
dopamine (movement),
serotonin (mood)
Neurotrophic factors NGF,
BDNF
All communication within
and between nerve cells
Newly published Nature Review
Article (September 2019):
“Axonal transport disruption is
linked to human neurological
conditions.”
Abnormal Transport
Shows the Blockage and Slowing of BDNF across the axon. Black areas demonstrate where
transport is slowed due to high levels of neurotoxic proteins.
TREATED WITH
The Flow and Speed of axonal transport is improved.
(120s)(88s)(88s)
APP, Ab42, C99 – Mobley, UCSD; aSYN – Isacson, Harvard; Lee, U.Penn;
Tau – U. Muenich & Zuerich; Htt – Mobley, UCSD; TDP43 – Taylor, Northwestern
Retrograde (0.5 frame/sec)
11
12. 12
RESULTS IN HUMANS
ANVS401 Lowers Neurotoxic Proteins in Spinal Fluid of MCI Patients
In this proof of concept study, ANVS401 lowers the levels of APP/Aβ, tau/p-tau and
αSYN back to the levels seen in healthy volunteers
It lowers the levels of the three neurotoxic proteins causing AD and PD
Maccecchini et al: JNNP 2012; 83: 894-902
13. 13
ANVS401 LOWERS NEUROTOXIC PROTEINS AND
INFLAMMATORY MARKERS
Maccecchini et al: JNNP 2012; 83: 894-902
CSF Biomarkers Significantly Decrease After 10
Days of Oral ANVS401 in MCI Patients
Human
Biomarker
CSF % of
Baseline
p-Value
sAPP α -59.9% 0.0006
sAPP β -57.7% 0.0001
Aβ42 -51.4% 0.053
Tau -46.2% 0.002
p-Tau -61.0% 0.0005
αSYN -41.2% 0.091
CSF Inflammatory Markers Significantly Decrease
After 10 Days of Oral ANVS401 in MCI Patients
Inflammatory
Protein
CSF % of
Baseline
p-Value
Complement C3 -86.9% 0.0007
MCP-1 -87.5% 0.0007
YKL40 -72.7% 0.0113
sCD14 -26.1% 0.1159
Factor FH* 23.7% 0.4988
* Control Factor
14. 14
TWO PHASE 3 CLINICAL TRIALS IN AD-DS AND PD
TWO PHASE 2 CLINICAL TRIALS IN AD AND PD
PATIENTS ENDPOINTS
AD with 24 patients for one month (ongoing)
PD with 50 patients for one month (planned)
Target Engagement
Decrease in neurotoxic protein levels
Pathway Engagement
Increase in neurotransmitters and neurotrophic factors
Lowering of inflammatory proteins
Lowering of neurodegeneration markers
Cognitive Outcomes and Functional Outcomes
PATIENTS ENDPOINTS
AD-DS with 100 patients for
24 months (testing for cognition every
6 months)
Cognitive Outcomes
PD with 400 patients for
18 months (testing for futility after
9 months)
Functional Outcomes
15. 15
RESULTS IN ANIMALS
19 animal studies showed that ANVS401 and ANVS405 improved the affected function
ANVS401 and ANVS405 increased memory and
learning in three animal models:
AD tg mice
DS trisomic mice
TBI rats
Improved gut motility in PD tg mice
Stabilized brain chemistry in FTD tau tg mice
Protected retinal cells in acute glaucoma in rats
16. 1% 2%
4%
8%
16%
47%
60-65 65-70 70-75 75-80 80-85 85+
16
MARKET PROJECTIONS
Source: Alzheimer‘s Association 2014; Incidence of AD in Relation to Age
Increase in Incidence with Aging of Population
Annual sales potential for US and worldwide
are over $100 billion dollars
17. CHIEF EXECUTIVES AND CHIEF ADVISORS
Jeffrey Cummings, MD, Chief Medical Advisor
Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts.
US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous
Diseases, Queen Square, London, England. Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the
Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, director of the Deane F. Johnson Center for Neurotherapeutics at
UCLA and director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Cleveland and Florida. He is past president
of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cummings has authored or edited 30
books and published nearly 600 peer-reviewed papers.
17
Maria L. Maccecchini, PhD Founder, President & CEO
Founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
Was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony
Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; General Manager of Bachem Bioscience, the US
subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt; Dr. Maccecchini did one postdoc at Caltech and
one at the Roche Institute of Immunology, her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at
The Rockefeller University.
Jeffrey McGroarty, CPA, MBA, Chief Financial Officer
Jeff is a financial executive with experience in investor relations, working with analysts, creditors and financial institutions, planning
and analysis, capital allocation, SEC communications and reporting, accounting, acquisitions and turnarounds. He is experienced in
effectively managing complex projects, building professional relations and developing staff. Mr. McGroarty was previously employed
as CFO of Safeguard Scientifics, Interim Controller at Cephalon, Inc., Vice President-Financial Planning and Analysis of Exide
Technologies, Inc., and Senior Manager at PWC. Jeff’s MBA is from the Wharton School of Business.
William Mobley, MD, PhD Chief Scientific Advisor
Distinguished Professor, Department of Neurosciences Florence Riford Chair for Alzheimer Research and Associate Dean for
Neurosciences Initiatives. He is a member of the National Academy of Medicine. His research focuses on the neurobiology of
neurotrophic factor actions/signaling and on the hypothesis that malfunction of these mechanisms contribute to neuronal
dysfunction in developmental and age-related disorders of the neurosystem.
18. SCIENTIFIC ADVISORY BOARD
18
Sidney Strickland, PhD, Chairman
Vice President and Dean for Educational Affairs
and Research Professor, Patricia and John
Rosenwald Laboratory of Neurobiology and
Genetics at Rockefeller University. Dr. Strickland’s
laboratory investigates how dysfunction of the
circulatory system contributes to Alzheimer’s and
other neurodegenerative disorders. He will serve as
the Chairman of Annovis Bio’s SAB.
Peter Davies, PhD
Peter Davies received his B.Sc. and Ph.D. both in
Biochemistry from the University of Leeds. He was
a post-doctoral fellow at the University of
Edinburgh, Scotland before joining the staff of the
Medical Research Council Brain Metabolism Unit
in Edinburgh in 1974, where he began his research
on Alzheimer’s disease. He is presently the Director
of the Litwin-Zucker Research Center.
Jeffrey Cummings, MD
Dr. Cummings completed Neurology residency and a
Fellowship in Behavioral Neurology at Boston University,
Massachusetts. US training was followed by a Research
Fellowship in Neuropathology and Neuropsychiatry at the
National Hospital for Nervous Diseases, London, England.
Dr. Cummings was formerly Professor of Neurology and
Psychiatry, Director of Alzheimer’s Disease Research and
Director of the Center for Neurotherapeutics at UCLA. He
was Director of the Cleveland Clinic Lou Ruvo Center for
Brain Health in Las Vegas, Cleveland and Florida.
William Mobley, MD, PhD
Dr. Mobley is Distinguished Professor, Department
of Neurosciences Florence Riford Chair for
Alzheimer Research and Associate Dean for
Neurosciences Initiatives. He is a member of the
National Academy of Medicine. His research
focuses on the neurobiology of neurotrophic
factor actions/signaling and on the hypothesis
that malfunction of these mechanisms contribute
to neuronal dysfunction in developmental and
age-related disorders of the neurosystem.
Gregory Petsko, PhD
He is a member of the National Academy of Sciences,
the National Academy of Medicine, the American
Academy of Arts and Sciences and the American
Philosophical Society. His research interests are directed
towards understanding the biochemical bases of
neurological diseases like Alzheimer’s, Parkinson’s, and
ALS discovering treatments (especially by using structure-
based drug design), that could therapeutically affect
those biochemical targets, and seeing any resulting drug
candidates tested in humans. He has also made key
contributions to the field of protein crystallography.
Rudolph E. Tanzi, PhD
Dr. Tanzi has published over 500 research papers and has
received the highest awards in his field, including the
Metropolitan Life Foundation Award, Potamkin Prize,
Ronald Reagan Award, Silver Innovator Award, and
many others. He was named to TIME magazine’s list of
TIME100 Most Influential People in the World (2015), and
received the Smithsonian American Ingenuity Award, the
top national award for invention and innovation. He co-
authored the popular trade books “Decoding Darkness”,
New York Times bestseller, “Super Brain”, and international
bestseller “Super Genes”.
19. 19
Michael B. Hoffman
Chairman
Mr. Hoffman is the Founder and Managing Partner
of Stone Capital Partners, a private equity firm
focused on power and renewable energy. He was
Partner of Riverstone, senior managing director at
the Blackstone Group and managing director at
Smith Barney, Harris Upham & Co. He serves as
Chairman of Onconova, Annovis Bio, Curative and
is on the Board of Rockefeller University.
Claudine E. Bruck, PhD
Pharmaceutical executive and scientist with strong
entrepreneurial drive. Exhibited successes in
building a therapeutic research unit de novo and
leading discovery and clinical development of
biological (vaccines, biopharmaceuticals) and
small molecule medicines as well as an ophthalmic
drug portfolio. With creativity and a strong results-
focus, she is energized to challenge and lead
teams. Extensive Pharmaceutical industry
experience spans drug discovery and
development across several therapeutic.
Mark White
Mark is a biopharmaceutical executive with
global marketing, business development and
sales experience. Currently, Mark is an
independent consultant and a member of Robin
Hood Ventures, a Philadelphia based angel
investor group. Previously, Mark held senior level
roles at Pfizer in marketing and commercial
development, where he led the successful global
launches of Inspira, Revatio, Lyrica and Xeljanz. In
his last position, he was Vice President
Worldwide Marketing, with global responsibility
for new product development and in-line
marketing for Pfizer’s Inflammation
Therapeutic Area.
Robert M. Whelan, Jr.
Mr. Whelan brings over 35 years of corporate
finance and investment banking experience to
Annovis’ Board of Directors. Since 2001, Mr.
Whelan has been President of Whelan &
Company, LLC, providing financial consulting,
valuation and strategic services to public and
private companies in the technology,
healthcare and alternative energy industries.
From 1999 to 2001, Mr. Whelan served as Vice
Chairman, Prudential Volpe Technology Group.
Prior to then, Mr. Whelan was a senior executive
with Volpe Brown Whelan, a private technology
and healthcare investment banking, brokerage
and asset management firm.
.
Maria L. Maccecchini, PhD
Executive Board Member
Founded Annovis in May 2008 to develop better
therapeutics for Alzheimer’s, Parkinson’s and other
neurodegenerative diseases. Founder and CEO of
Symphony Pharmaceuticals/Annovis focused on
protecting brain cells after stroke. It sold in 2001 to
Transgenomic.
BOARD OF DIRECTORS
20. INVESTMENT SUMMARY
A novel approach to treat neurodegeneration is desperately needed
The markets for AD and PD drugs are in the multibillions of dollars
and growing
Annovis has a novel solution to stop the course of AD and PD
ANVS401 improves axonal transport and homeostasis in the
brain and recovers the affected function
The successful completion of our two Phase 2a studies will
provide optimal information on target and pathway
engagement in AD and PD and allows us to move to two Phase
3 studies
20
21. Improves THE FLOW of Axonal Transport
in Alzheimer’s Disease and
Neurodegeneration
CONTACT US
1055 Westlakes Drive
Suite 300
Berwyn, PA 19312
+1 (610) 727 3913
info@annovisbio.com
www.annovisbio.comSymbol: ANVS (NYSE American)